Menu Search
Equities

Pell Bio Med Technology Co Ltd

6949:TAI

Pell Bio Med Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)82.00
  • Today's Change0.90 / 1.11%
  • Shares traded11.00k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in TWDIncome statement in TWDView more

Year on year Pell Bio Med Technology Co Ltd had net income fall 73.27% from a loss of 230.13m to a larger loss of 398.76m despite a 5.11% increase in revenues from 17.16m to 18.03m. An increase in the selling, general and administrative costs as a percentage of sales from 476.37% to 805.67% was a component in the falling net income despite rising revenues.
Gross margin-113.22%
Net profit margin-2,262.16%
Operating margin-2,360.14%
Return on assets-29.90%
Return on equity-39.58%
Return on investment-34.86%
More ▼

Cash flow in TWDView more

In 2023, Pell Bio Med Technology Co Ltd did not generate a significant amount of cash. Cash Flow from Financing totalled 594.89m or 3,298.92% of revenues. In addition the company used 179.99m for operations while cash used for investing totalled 419.63m.
Cash flow per share-6.84
Price/Cash flow per share--
Book value per share23.77
Tangible book value per share23.73
More ▼

Balance sheet in TWDView more

Pell Bio Med Technology Co Ltd has a Debt to Total Capital ratio of 9.85%, a lower figure than the previous year's 23.44%.
Current ratio7.21
Quick ratio7.19
Total debt/total equity0.1181
Total debt/total capital0.0985
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.